KPTI

7.95

4.67% -0.40

Dopo l'orario di chiusura: 7.95

Karyopharm Therapeutics Inc (KPTI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$8.35

Aprire:

$8.7

Volume 24 ore:

120.74K

Relative Volume:

1.60

Capitalizzazione di mercato:

$70.27M

Reddito:

$140.46M

Utile/perdita netta:

$-146.34M

Rapporto P/E:

-6.2598

EPS:

-1.27

Flusso di cassa netto:

$-117.73M

1 W Prestazione:

-11.32%

1M Prestazione:

-22.19%

6M Prestazione:

-32.14%

1 anno Prestazione:

-60.10%

Intervallo 1D:

$7.885

$8.70

Intervallo di 1 settimana:

$7.611

$10.38

Portata 52W:

$7.611

$25.50

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Nome

Karyopharm Therapeutics Inc

Settore

Healthcare (1189)

Industria

Biotechnology (675)

Telefono

617-658-0600

Indirizzo

85 WELLS AVENUE, NEWTON, MA

Dipendente

279

Cinguettio

@Karyopharm

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

KPTI's Discussions on Twitter

Confronta KPTI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KPTI Karyopharm Therapeutics Inc	7.95	70.27M	140.46M	-146.34M	-117.73M	-1.27
VRTX Vertex Pharmaceuticals Inc	479.79	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	698.74	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.67	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.75	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	271.80	29.71B	3.32B	-860.46M	-1.04B	-8.32

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-01-19	Iniziato	Piper Sandler	Overweight
2022-11-04	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2022-02-09	Aggiornamento	JP Morgan	Underweight → Neutral
2021-11-19	Ripresa	Morgan Stanley	Equal-Weight
2021-08-06	Downgrade	JP Morgan	Overweight → Neutral
2021-08-06	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-08-06	Downgrade	SVB Leerink	Outperform → Mkt Perform
2020-07-02	Iniziato	Morgan Stanley	Overweight
2020-03-04	Iniziato	Barclays	Overweight
2020-01-17	Downgrade	Wedbush	Outperform → Neutral
2019-07-23	Aggiornamento	JP Morgan	Neutral → Overweight
2019-07-05	Reiterato	H.C. Wainwright	Buy
2019-07-05	Reiterato	Robert W. Baird	Outperform
2019-03-01	Downgrade	JP Morgan	Overweight → Neutral
2019-02-28	Reiterato	BofA/Merrill	Underperform
2019-02-27	Downgrade	BofA/Merrill	Neutral → Underperform
2019-01-03	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-12-03	Iniziato	B. Riley FBR	Buy
2018-11-09	Aggiornamento	Wedbush	Neutral → Outperform
2018-05-24	Downgrade	Wedbush	Outperform → Neutral
2018-04-02	Ripresa	Leerink Partners	Outperform
2017-11-15	Ripresa	H.C. Wainwright	Buy
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2016-09-08	Reiterato	H.C. Wainwright	Buy
2016-08-30	Aggiornamento	Jefferies	Hold → Buy
2016-08-18	Iniziato	H.C. Wainwright	Buy
2016-06-28	Iniziato	Robert W. Baird	Outperform

Mostra tutto

Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie

Feb 27, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Feb 26, 2025

Karyopharm Therapeutics Inc.'s SWOT analysis: biotech firm's stock faces pivotal year - Investing.com

Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Feb 26, 2025

Feb 25, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia

Feb 25, 2025

Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa

Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com

Feb 24, 2025

Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq

Feb 24, 2025

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com

Feb 24, 2025

Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune

Feb 24, 2025

Karyopharm announces 1-for-15 reverse stock split - MSN

Feb 24, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa

Feb 24, 2025

Can Karyopharm's 15:1 Reverse Split Save Its Nasdaq Listing? - StockTitan

Feb 24, 2025

Karyopharm Therapeutics' (KPTI) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Feb 24, 2025

Feb 23, 2025

Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World

Feb 23, 2025

Feb 22, 2025

Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks

Feb 22, 2025

Feb 21, 2025

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Feb 21, 2025

Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa

Feb 20, 2025

Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks

Feb 20, 2025

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks

Feb 20, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target - Investing.com India

Feb 20, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 20, 2025

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Feb 20, 2025